在心肌梗塞的二次预防中使用阿司匹林:系统性审查和元分析
Badrudduza Al Maimani1, Ruma Akhter2, Somya Binte Akhond3
1Department of Internal Medicine, Mukti Hospital, Comilla, BGD.
Cureus
|November 24, 2025
概括
阿司匹林有效地预防了复发性心肌梗塞 (MI),但增加了出血风险. 较新的P2Y12抑制剂在较少出血的情况下提供类似的益处,这表明针对二次性MI预防的个性化抗血小板治疗.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 阿司匹林是二次性预防心肌梗塞 (MI) 的标准治疗方法.
- 对阿司匹林与较新的抗血小板药物的比较有效性和安全性进行了辩论.
- 优化抗血小板策略对于管理MI后的患者至关重要.
研究的目的:
- 评估阿司匹林在二次性心脏病发作预防中的有效性和安全性.
- 将阿司匹林与其他抗血小板疗法进行比较.
- 确定二次性心脏病发作预防的最佳个性化策略.
主要方法:
- 一个符合PRISMA的14项研究 (n=327,987) 的元分析,这些研究在2000-2024年间发表.
- 随机效应模型被用来组合心血管和出血事件的风险比率.
- 根据剂量,并发症和治疗策略进行了子组分析.
主要成果:
- 阿司匹林减少了19%的复发事件,但增加了出血风险,特别是325毫克.
- P2Y12 抑制剂的疗效与降低出血风险相比较.
- 扩展双重抗血小板治疗 (DAPT) 对高风险患者有好处,但增加了出血;单一治疗的异质性较低.
结论:
- 阿司匹林仍然是二次性心脏病发作预防的基石.
- 个性化策略,包括81毫克阿司匹林,高出血风险患者的P2Y12抑制剂,以及高缺血风险患者的时间有限的DAPT,优化了结果.
- 个性化抗血小板治疗是平衡二次性心脏病预防中的有效性和安全性的关键.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Angina IV: Management
222
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
222
Acute Coronary Syndrome IV: Interprofessional Care
203
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
203
Atherosclerosis III: Management
301
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
301
Coronary Artery Disease V: Interprofessional Care
206
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
206
Coronary Artery Disease IV: Preventive Measures
577
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
577


